amgen glp-1 drug Amgen's obesity drug: what you need to know about MariTide Patent and Innovation Trends in
Description
Mechanistic studies should aim to elucidate how GLP-1RAs influence endothelial function, inflammation, and myocardial remodeling in HFpEF
...and so much more
At the end of the trial, mean weight loss of 4.4% is reported in the combination group, compared to 1.6% for placebo
In other words, just because you hit your goal weight doesnt mean you can stop taking the medications that helped you lose it
The Journal of Pharmacology and Experimental Therapeutics
The other authors report no conflicts of interest
